Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice

✍ Scribed by Y. Matsumoto; I. Saiki; J. Murata; H. Okuyama; M. Tamura; I. Azuma

• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: French
• Weight: 745 KB
• Volume: 49
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910490323

✦ Synopsis

Abstract

We studied the effects of in vivo administrations of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) on the metastasis of murine hematogenous and non‐hematogenous tumors in spontaneous and experimental metastasis models. Spontaneous lung metastasis caused by intra‐footpad injections of B16‐BL6 melanoma and Lewis‐lung‐carcinoma (3LL) cells were inhibited by intravenous (i.v.) and subcutaneous (s.c.) injections of rhG‐CSF after excision of the primary tumors. Recombinant hG‐CSF significantly inhibited liver metastasis when administered i.v. after i.v. injection of L5178Y‐ML25 T‐lymphoma cells. Multiple i.v. administration of rhG‐CSF after the tumor inoculation prolonged the survival times of mice inoculated i.v. with L5178Y‐ML25 lymphoma cells. Recombinant hG‐CSF did not directly affect the growth of B16‐BL6 and L5178Y‐ML25 cells in vitro. During the administration periods, both i.v. and s.c. injections of rhG‐CSF increased the number of total white blood cells (WBC) in peripheral blood to approximately 3 times the normal level in normal and tumor‐bearing mice. We also found that the administration of rhG‐CSF stimulates neutrophils to become cytostatic against these tumor cells. Our results indicate that the injection of rhG‐CSF is effective in inhibiting lung and liver metastases by activating neutrophils and increasing cell number.